Hillman Fellows Program

2018-2019 Hillman Fellows for Innovative Cancer Research Program

Building on our long and fruitful partnership with Hillman Family Foundations, we at UPMC Hillman Cancer Center are honored to embark upon a new era of collaboration through the recently redesigned Hillman Fellows for Innovative Cancer Research Program. Over the next ten years, Henry L. Hillman Foundation has pledged a significant investment in our comprehensive program, with the goal of supporting several key areas that are of strategic importance to our mission of reducing the burden of cancer. Areas supported by this program include recruitment of top-tier senior and early-career faculty, as well as funding of highly innovative developmental research projects and transdisciplinary collaborative research efforts. The program also supports a new competitive opportunity for postdoctoral candidates, which is currently accepting applications (see: www.UPMCHillman.com/PostdoctoralFellowship).

We are excited to announce the new Hillman Fellows for Innovative Cancer Research for the award period of July 1, 2018 through June 30, 2019.

Hillman Fellows for Innovative Cancer Research

A key priority of UPMC Hillman Cancer Center is the recruitment of exceptional faculty across multiple research areas, including the recruitment of senior-level investigators of national and international renown who will serve in visionary leadership positions within the institution. After national searches, two highly accomplished individuals have joined the faculty to lead Hillman research programs as 2018 Hillman Fellows:

Ronald Buckanovich, MD, PhD, arrived in September 2017 as Professor of Medicine and of Obstetrics, Gynecology and Reproductive Sciences as well as Co-Leader of Hillman Breast and Ovarian Cancer Program and Co-Director of the UPMC Ovarian Cancer Center of Excellence. In addition, he was recently appointed as Co-Director of the Women’s Cancer Research Center, which is a collaboration between UPMC Hillman Cancer Center and Magee-Womens Research Institute. Dr. Buckanovich is playing an integral role in establishing a Comprehensive Ovarian Biology Research Center, which brings together biology and oncology researchers to study the molecular and physiological factors that mediate the development of ovarian cancer, his area of expertise.

Shou-Jiang (SJ) Gao, PhD joined the faculty in April 2018 as The Pittsburgh Foundation Endowed Chair in Drug Development for Immunotherapy, Professor of Microbiology and Molecular Genetics, and Leader of the Hillman Cancer Virology Program. A leading expert in tumor virology, Dr. Gao developed the first genetic system for studying Kaposi’s sarcoma-associated herpesvirus (KSHV), as well as several KSHV infection and cellular transformation models, which were used to define the mechanisms of KSHV infection and oncogenesis. This work has led to the identification of numerous targeted and immunotherapy-based strategies for treating KSHV-induced cancers.

Hillman Fellows for Innovative Early-Career Cancer Research

As a way to augment current research strengths and enhance expertise in new and promising disciplines, we have recruited three exceptional junior investigators to UPMC Hillman Cancer Center who will begin their academic careers as Hillman Fellows:

Lan Coffman, MD, an Assistant Professor of Medicine and a member of the Hillman Breast and Ovarian Cancer Program, specializes in the treatment and study of ovarian cancer. She is particularly interested in understanding how carcinoma-associated mesenchymal stem cells (CA-MSCs) develop within the tumor microenvironment (defined as the area surrounding the tumor that contains blood vessels and immune and stromal cells), and how they act to promote ovarian cancer growth. Recent findings in her laboratory demonstrated that cancer cells act to transform normal mesenchymal stem cells into CA-MSCs by inducing epigenetic modifications to DNA that lead to alterations in gene expression (i.e., the amount of protein-coding RNA that gets transcribed).

Hung Luu, MD, PhD, MPH is an Assistant Professor of Epidemiology and a member of the Hillman Cancer Epidemiology and Prevention Program. Dr. Luu’s research applies advanced molecular technologies to the investigation of genetic and environmental factors that influence cancer development, with the ultimate goal of translating new discoveries into improved methods of cancer prevention and treatment.

Yana Najjar, MD is an Assistant Professor of Medicine, a member of the Hillman Melanoma Program, and a medical oncologist specializing in the treatment of melanoma. Her research focuses on cancer immunotherapy and its impact on the tumor microenvironment and peripheral immune system.

Hillman Fellows for Innovative Developmental Cancer Research

Developmental high-risk/high-reward projects hold the greatest promise for new discoveries that could eventually reshape medical practice. To promote groundbreaking research, our Hillman Fellows program will support eight cancer pilot projects that were chosen after a Cancer Center-wide solicitation of proposals. The Cancer Center leadership selected these projects, which span the breadth of novel research being done at Hillman, based on their scientific merit, innovation, significance, and approach.

Maninjay Atianand, PhD, Assistant Professor of Immunology: Long noncoding RNAs as regulatory checkpoints in tumor-associated macrophages

In this pilot project, Dr. Atianand’s laboratory will determine the role of long noncoding RNAs (lncRNAs) (RNA transcripts that do not get translated into proteins) in controlling immune cell functions in the tumor microenvironment. In particular, his team will characterize the expression of the lncRNAs found in tumor-associated macrophages in melanoma, and explore their role in antitumor immunity using mouse models. It is anticipated that these studies will reveal new translational targets as well as biomarkers that predict response to cancer immunotherapies.

Randall Brand, MD, Professor of Medicine and of Human Genetics and a member of the Hillman Cancer Epidemiology and Prevention Program: Characterization of chromatin environment on cancer risk and inflammation in Lynch Syndrome

Individuals with Lynch Syndrome harbor a mutation in at least one of the main DNA repair genes, greatly increasing their risk for colorectal cancer (CRC). However, not everyone with these mutations will develop CRC. This pilot project aims to understand changes in how DNA is packaged with RNA and histone proteins in response to environmental stressors/inflammatory stimuli in Lynch Syndrome patients, and the relationship of these changes to cancer risk. This project will facilitate the development of novel cancer prevention approaches and the identification of new surrogate markers to evaluate the efficacy of preventive agents. The long-term goal is to personalize CRC prevention by identifying biomarkers associated with cancer risk that can be easily monitored and applied to not only individuals with Lynch Syndrome, but to the general population as well.

Xin Huang, PhD, Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences and a member of the Hillman Breast and Ovarian Cancer Program: miR-210 function in clear cell renal cell carcinoma

The hypoxia responsive pathway, normally induced by low oxygen, is nearly always upregulated (i.e., increased) in clear cell renal cell carcinoma (ccRCC), making its components attractive therapeutic targets. Dr. Huang’s laboratory found that hypoxia induces robust expression of a particular molecule, microRNA (miR)-210, in a variety of cancerous cell lines through the RNA transcription regulating factors hypoxia-inducible factors (HIF) 1-alpha and 2-alpha. Notably, miR-210 is one of the most highly expressed miRNAs in ccRCC as compared with normal tissue, and its overexpression correlates with poor overall patient survival. Based on this evidence and the fact that microRNA can alter cell activity through silencing of gene expression, the Huang laboratory seeks to delineate the role of miR-210 in ccRCC tumorigenesis as well as test its potential as a therapeutic target in this pilot project.

Bruce Jacobs, MD, MPH, Assistant Professor of Urology: Effects of cancer care centralization on geographic, racial, ethnic and socioeconomic disparities

In recent decades, health care delivery for patients with cancer has undergone a dramatic shift whereby care is increasingly centralized in ‘centers of excellence’ with high patient volume. This shift has an immense potential to improve patient outcomes, since many studies suggest that high-volume centers demonstrate improved survival. Although centralization appears to improve outcomes for patients receiving care at these high-volume centers, the overall effects of centralization remain unknown. The goal of Dr. Jacob’s pilot project is to determine the impact of centralization on the cancer care received by subgroups of patients who differ with respect to geographic location, race, ethnicity, and socioeconomic status.

Xinghau Lu, MD, PhD, Professor of Biomedical Informatics and a member of the Hillman Molecular and Cellular Cancer Biology Program: Developing an artificial intelligence-based clinical decision support system for precision oncology

The pilot project from the Lu laboratory aims to develop artificial intelligence methods to assist clinical decision making. The investigators will collect clinical data from non-small cell lung cancer (NSCLC) patients treated at UPMC Hillman Cancer Center to discover how patterns of treatment influence clinical outcomes in patients with specific characteristics. The overarching goal is to use such information to develop decision support systems enabling oncologists to personalize therapies for each individual NSCLC patient.

Roderick O’Sullivan, PhD, Assistant Professor of Pharmacology and Chemical Biology and a member of the Hillman Molecular and Cellular Cancer Biology Program: Effects of telomerase inhibition in neuroblastoma

Telomerase is the specialized enzyme responsible for de novo synthesis of new telomeric DNA at chromosome ends. Increased expression (amount) and activity of telomerase is a defining hallmark of cancer cells, whereas normal cells rarely express it, fueling the hypothesis that telomerase inhibition is an Achilles’ heel for cancer. The goal of this pilot project is to adapt and apply a highly innovative CRISPR-Cas9-based gene editing strategy to rapidly, yet reversibly, remove telomerase from cancer cells and decipher the effects of telomerase inhibition in a clinically relevant model of neuroblastoma (a type of brain cancer diagnosed in both adults and children).

Shilpa Sant, PhD, Assistant Professor of Pharmaceutical Sciences and member of the Hillman Breast and Ovarian Cancer Program: Role of pathological microcalcifications in the primary tumor progression

Breast cancer is frequently detected by the presence of calcium deposits (microcalcifications) seen on mammograms. Studies suggest that the microcalcifications are a risk factor for breast cancer progression, but whether they cause or are just a result of the disease remains unknown. However, there does appear to be a link between microcalcifications, specifically those with the calcium-containing mineral hydroxyapatite, and cancer cells acquiring a mesenchymal phenotype (cells that gain the migratory and invasive properties needed for metastasis). Moreover, evidence suggests a link between microcalcifications and breast cancer cells overexpressing bone markers and metastasizing to the bone. In this pilot project, the Sant laboratory will develop in vitro and in vivo approaches to elucidate the functional role that microcalcifications may play in tumor invasion, bone mimicry and subsequent risk of bone metastasis.

Shivendra Singh, PhD, UPMC Chair in Cancer Prevention Research, Professor of Pharmacology and Chemical Biology and of Urology, Hillman Associate Director for Basic Research, and member of the Hillman Breast and Ovarian Cancer and Cancer Epidemiology and Prevention Programs: A novel strategy for prevention of breast cancer-induced osteolytic bone resorption

Osteolytic bone erosion leading to pain is a serious complication in women with metastatic breast cancer. The goal of this project is to determine the activity of a novel plant-based regimen in preventing bone erosion.

Hillman Fellows for Innovative Team Science Cancer Research

The ability to move the cancer field forward often requires a multi-disciplinary approach. Medical oncologist, cancer epigenetics researcher, and Leader of the Hillman Lung Cancer Program, James Herman, MD, has teamed up with cancer epidemiologist and Co-Leader of the Hillman Cancer Epidemiology and Prevention Program, Jian-Min Yuan, MD, PhD, and pulmonologist David Wilson, MD, MPH, on the Pittsburgh Lung Cancer Screening Study (PLuSS), a community-based research cohort of current and ex-smokers, screened with low-dose helical computed tomography (CT) and followed for development of lung cancer since 2002. PLuSS has provided the basis for continual improvements in CT screening for individuals at high risk for developing lung cancer, a method that has been shown to reduce lung cancer mortality. In addition to the CT scan results, biological fluids including blood, sputum, and urine are collected from study participants, and provide an invaluable resource for Hillman investigators to conduct a wide range of research studies, such as genome-wide analysis of molecular changes in lung cancer, and the development of novel cancer biomarkers for further-improved detection (i.e., fewer false positives and false negatives with screening), diagnosis, and therapeutic monitoring. This project was selected for support through the Hillman Fellows Program by Cancer Center leadership due to its potential for high impact and reach across our vast community network.

All Hillman Fellows and Projects

Theme: Lung Cancer Detection and Treatment
James Herman, MD Discovering DNA Methylation in Lung Cancer for Predictive and Early Detection Biomarkers
Timothy Burns, MD, PhD Targeting the TWIST1-E2A Pathway to Overcome Acquired Resistence to Erlotinib in EGFR Mutant NSCLC
Theme: Breast Cancer Prevention and Treatment
Steffi Oesterreich, PhD Novel Pathways Mediating Endocrine Resistance in Invasive Lobular Breast Cancer
Carola Neumann, MD A Role for the Peroxidase PRDX1 to Prevent Breast Cancer by Protecting Rad51 from Oxidation-Induced Inactivation
Mei Zhang, PhD Characterization and Targeting of Cell Respiration of Tumor-Initiating Cells in Breast Cancer
Theme: Genome Instability, DNA Repair, and Aging
Bennett Van Houten, PhD Dynamics and Protein Interactions During Nucleotide Excision Repair
Roderick O'Sullivan, PhD Inhibition of the Alternative Lengthening of Telomeres in Human Cancer Cells
Theme: Technology for Precision Medicine
William LaFramboise, PhD Diagnostic Sequencing of Solid Tumors
Lisa Butterfield, PhD Antigen-Engineered Dendritic Cell Vaccine +/- IFNα-2b Boost for Melanoma
Theme: Lung Cancer Prevention and Treatment
James Herman, MD Discovering DNA Methylation in Lung Cancer for Predictive and Early Detection Biomarkers
Timothy Burns, MD, PhD The Development of TWIST1 Inhibitors for the Treatment of Oncogene-Driven Lung Cancer
Linda Robertson, RN, MSN, DrPH Outreach Efforts to Increase Smoking Cessation in Individuals at High Risk for Lung Cancer
Theme: Fostering the Next Generation of Scientists
Masahiro Shuda, PhD Role of Mitotic 4E-BP1 Phosphorylation in Carcinogenesis
Kathy Shair, PhD The Combined Oncogenic Properties of Epstein-Barr Virus LMP1 and LMP2A Proteins
Mei Zhang, PhD Cancer-Associated Fibroblasts and the Metastatic Capacity of Breast Cancer Stem Cells
Roderick O'Sullivan, PhD Inhibition of the Alternative Lengthening of Telomeres in Human Cancer Cells
Theme: Technology for Precision Medicine
William LaFramboise, PhD Diagnostic Targeted Deep Sequencing of Solid Tumors
Lisa Butterfield, PhD Antigen-Engineered Dendritic Cell Vaccine +/- IFNα-2b Boost for Melanoma
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Edward Chu, MD Protein Kinase D as a Potential Target for the Treatment of Colorectal Cancer
Laura Stabile, PhD James Herman, MD Molecular Phenotyping of Lung Cancer
Jian Yu, PhD Lin Zhang, PhD Intestinal Protection Against Chemotherapy by a Novel PUMA Inhibitor
Theme: Molecular Mechanisms of Cancer Development and Progression
Roderick O'Sullivan, PhD p16/p53-Independent Induction of Senescence by Disruption of Anti-Silencing Function 1
Theme: Technology for Precision Medicine
William LaFramboise, PhD Rebecca Jacobson, MD Uma Chandran, PhD, MSIS Diagnostic Targeted Deep Sequencing of Renal Cell Carcinoma
Nathan Yates, PhD Application of a Novel Proteomic Method and Apparatus for Multi-Dimensional Analysis of Tissue and Plasma Samples
Jan Beumer, PharmD, PhD John Schmitz, PhD Julie Eiseman, PhD Protein Kinase D as a Potential Target for Colorectal Cancer
Lisa Butterfield, PhD Antigen-Engineered Dendritic Cell Vaccine +/- IFNα-2b Boost for Melanoma
Theme: Fostering the Next Generation of Scientists
Timothy Burns, MD, PhD Defining the Role of TWIST1 in Oncogene-Driven Lung Adenocarcinoma
Kathy Shair, PhD The Combined Oncogenic Properties of Epstein-Barr Virus LMP1 and LMP2A Proteins
Mei Zhang, PhD Cancer-Associated Fibroblasts and the Metastatic Capacity of Breast Cancer Stem Cells
Theme: Molecular Mechanisms of Cancer Development and Progression
Carola Neumann, MD The Role of Prdx1 in DNA Repair
Kathy Shair, PhD The Combined Oncogenic Properties of Epstein-Barr Virus LMP1 and LMP2A
Yong Wan, PhD The Role of KLF4 in Breast Cancer
Gutian Xiao, PhD PDLIM2 in Cancer Biology and Therapy
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Timothy Burns, MD, PhD Defining the Role of TWIST1 in Oncogene-Driven Lung Adenocarcinoma
Lesley Butler, MSPH, PhD Matrix Metalloproteinases and Related Compounds as Urinary Biomarkers for Breast Cancer
Adrian Lee, PhD Targeting Insulin-Like Growth Factor Receptor in Triple Negative Breast Cancer
Saumendra Sarkar, PhD The Role of RIPK1 in Head and Neck Squamous Cell Carcinoma Metastasis
Theme: Cancer Stem Cells
Shivendra Singh, PhD Targeting of Breast Cancer Stem Cells by Dietary Agents
Mei Zhang, PhD Defining the Role of the Cancer Stem Cell Niche in Breast Cancer
Theme: Molecular Mechanisms of Cancer Development and Progression
Kara Bernstein, PhD Elucidating the Function of the Shu Complex during DNA Repair and DNA Replication
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Edward Chu, MD Development of Novel Chinese Herbal Medicines for the Treatment of Colorectal Cancer
Steffi Oesterreich, PhD Endocrine Resistance in Invasive Lobular Cancer
Nathan Yates, PhD Differential Mass Spectrometry: An Open Analytical Platform for the Discovery and Translation of Molecular Biomarkers
Theme: Cancer Risk, Prevention, and Survivorship
Ellen Beckjord, PhD, MPH Promoting Health and Wellness in Adult Cancer Survivors
Charles Horn, PhD Selective Breeding of Emesis in Musk Shrews
Jian-Min Yuan, MD, PhD Volatile Organic Carcinogen and Toxicant Biomarkers in Relation to Lung Cancer Risk Among Lifelong Nonsmokers
Theme: Cancer Immunology and Immunotherapy
Pawel Kalinski, MD, PhD Phase I/II Trials of Alpha-DC1 Vaccines in Prostate and Ovarian Cancers
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
William Bigbee, PhD Proteomics-Based Lung Cancer Biomarker Discovery and Validation
Shi-Yuan Cheng, PhD Mechanisms and Inhibition of Anti-Angiogenic Therapy-Induced Glioma Invasion
William LaFramboise, PhD Targeted Sequencing of Tumor Specific Renal Cell Carcinoma Chromosomal Regions Identified by High Density SNP Analysis
Anna Lokshin, PhD Urine Biomarkers for Early Detection and Diagnosis of Pancreatic Cancer
Hannah Rabinowich, PhD An Unexpected Target for Autophagy Inhibition: Implications for Breast Cancer Therapy
Hussein Tawbi, MD, PhD The Role of RASSF4 Gene in Melanoma Resistance to Cytotoxic Chemotherapy
Theme: Cancer Immunology and Immunotherapy
Dorothea Becker, PhD Molecular Analysis and Targeting of Pertinent Oxidative Stress-Response Genes that Shield Advanced Melanoma from Immunosuppression
Soldano Ferrone, MD, PhD Xinhui Wang, PhD Combinational Therapy for Triple Negative Breast Cancer
Saumendra Sarkar, PhD Role of TLR Signaling in the Chemopreventive Properties/Actions of Naturally Occurring Isothiocyanates
Theresa Whiteside, PhD A Prospective Study of the Effects of Chemoradiotherapy on Regulatory T Cells (Treg) in the Peripheral Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck
Theme: Molecular Mechanisms of Cancer Development and Progression
Dorothea Becker, PhD Analysis of ATM Expression and Function in Advanced-Stage Melanomas
Shi-Yuan Cheng, PhD Signaling Mechanisms in Glioma Invasion
Ole Gjoerup, PhD Investigating Basic Cancer Mechanisms using Polyomavirus Large T Antigen Models
Jing Hu, MD, PhD Histone Deacetylase 2 in Human Cancer: Role of Sumoylation-Promoting Activity
Bennett Van Houten, PhD Single-Molecule Analysis of Nucleotide Excision Repair Proteins
Yong Wan, PhD Regulation of Tumor Microenvironment by APC-Separase in Breast Carcinogenesis
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Albert Donnenberg, PhD Vera Donnenberg, PhD Targeting Treatment Resistance through the Sonic Hedgehog Pathway in Breast Cancer
Stefan Duensing, MD Anette Duensing, MD Understanding Cancer and Cancer Drugs to Develop Novel Approaches for Prevention and Treatment
William LaFramboise, PhD Identification of a MicroRNA Biomarker Signature for Early Diagnosis and Prognosis of Prostate Cancer
Robert Sobol, PhD Tumor Selective Chemotherapy for Glioblastoma: Exploiting Tumor-Specific Defects in NAD+ Biosynthesis
Hussein Tawbi, MD, PhD Modulation of DNA Repair: Tripartite Inhibition of DNA Repair Pathways using the Combination of Temozolomide, Decitabine, and ABT-888
Qingde Wang, MD, PhD Eradicating Leukemic Cells by Targeting ADAR1
Erik Wiener, PhD A Multistep Targeting Approach to MRI-Based Imaging for Diagnosing Cancer and Treatment Response
Lin Zhang, PhD Jian Yu, PhD Cell Death Control in Cancer Chemotherapy and Chemoprevention
Theme: Cancer Risk, Prevention, and Survivorship
Talal El Hefnawy, MD, PhD Toward Functional Probiotics that Reduce the Risk of Cancer
Theme: Cancer Immunology and Immunotherapy
Soldano Ferrone, MD, PhD Adoptive Immunotherapy of Melanoma with Transduced T Cells
Stephen Thorne, PhD Use of Oncolytic Viruses to Enhance Immunotherapy of Cancers
Nikola Vujanovic, MD, PhD NK Cell-Dendritic Cell Interaction in Cancer
XinHui Wang, PhD Development of CSPG4-Specific Monoclonal Antibody-Based Immunotherapy for Triple Negative Breast Cancer
Theme: Pilot Projects
Michael Gibson, MD, PhD The establishment of primary esophageal adenocarcinoma (EAC) heterotransplants will facilitate development of a representative model for preclinical analysis of targeted therapy for EAC that is based on human tumors obtained from patients, which can be used to study mechanisms of drug resistance and to explore future treatments to overcome this resistance.
Daniel Johnson, PhD My laboratory works to develop novel therapeutic strategies for acute myeloid leukemia (AML). We will seek to determine how dasatinib inhibition of SFK proteins leads to restoration of differentiation in AML cells.
Bo Liu, PhD The goal of our study is to understand how APC and Axin proteins function in the auto-feedback loop, with the objective of identifying critical targets useful for cancer prevention and therapy.
Theme: Molecular Mechanisms of Cancer Development and Progression
Dorothea Becker, PhD Functional Analysis of the p53 Upstream Regulators ASPP1, ASPP2, and iASPP in Advanced-Stage Melanomas
Ole Gjoerup, PhD Investigating Basic Cancer Mechanisms using a Viral T Antigen Model
Laura Niedernhofer, MD, PhD Identifying the Cause and Treatments for Age-Related Diseases
Richard Steinman, MD, PhD Stromal Therapeutics: Identifying and Interrupting Signals between Normal Cells and Cancer Cells that Contact Them
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Jan Beumer, PharmD, PhD Potentiation of Gemcitabine Cell Toxicity with ABT-888 with a Focus on Pancreatic Cancer
William Bigbee, PhD Proteomics-Based Lung Cancer Biomarker Discovery
Daniel Johnson, PhD Laboratory Studies to Support the Development of Investigator-Initiated Clinical Trials in Acute Myeloid Leukemia
Luyuan Li, PhD Nanoparticle-siRNA Mediated Multiple-Gene Silencing for the Treatment of Lung Cancer
Hannah Rabinowich, PhD Modulation of Autophagy to Circumvent Resistance to Chemotherapy of Apoptosis-Defective Breast Cancer Cells
Saumendra Sarkar, PhD Novel Modifiers of Toll-like Receptor Signaling
Hussein Tawbi, MD, PhD Abrogation of Chemotherapy Resistance in Metastatic Melanoma: The Inhibition of Histone Deacetylation and PARP in Combination with Carboplatin and Paclitaxel
Stephen Thorne, PhD Identifying Differences in Glycoprotein Motifs on Tumor and Non-Tumor Cells for Targeting with Biological Therapies
Theme: Cancer Risk, Prevention, and Survivorship
Dana Bovbjerg, PhD Gynecological Cancer Surgery: Mind-Body Effects in the Patient Experience
Wenjun Wang, MD, PhD Tanshinone IIA as a Chemopreventive Agent for Melanoma
Theme: Cancer Stem Cells
William LaFramboise, PhD Identification of Stem Cells in Normal Prostate and Prostate Cancer as an Underlying Source of Tumor Formation
Jonathan Pollett, PhD Concomitant Signal-Induced Transformation of Stem Cells
Theme: Cancer Immunology and Immunotherapy
Anthony Brickner, PhD Identifying Minor Histocompatibility Antigens Suitable for Immunotherapy of Leukemia and Lymphoma via High-Throughput Genome-Wide Association Studies
Hassane Zarour, MD The Role of PD-1 Expression in the Reversion of Tumor Antigen-Specific CD8+ T Cell Dysfunction
Theme: Molecular Mechanisms of Cancer Development and Progression
Pamela Hershberger, PhD How Do Lung Cancer Cells Escape the Growth Inhibitory Effects of Vitamin D?
Jing Hu, MD, PhD Regulation of Protein Translation by SUMO Conjugating Pathway
Frank Jenkins, PhD Role of Infection, Inflammation, and Genetics in Prostate Cancer
Deric Park, MD Growth and Differentiation Control of Glioblastoma Multiforme Cancer Stem Cells through the Notch-1-Stat3 Signaling Pathway
Gutian Xiao, PhD Autophagy and Nuclear Factor Kappa-B in Cancer Formation and Cancer Therapy
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Nathan Bahary, MD, PhD Using Zebrafish as a Model to Define Novel Genes and Pathways for New Prevention, Diagnostic, and Treatment Approaches for Human GI Malignancies
Thomas Conrads, PhD Paired Stable Isotope Metabolic Tracers (PSIMT): A Novel Approach for Elucidation and Discovery of Drug Metabolites
Elieser Gorelik, MD, PhD Chemotherapeutic Drugs and Tumor Cytokine Network
Jean Latimer, PhD Biomarkers of Pre-invasive Breast Cancer Aggressiveness
Monica Panelli, PhD Immunogenomic/Immunoproteomic Studies using Banked Melanoma Tissue and Blood Samples
Qingde Wang, MD, PhD New Strategy for Leukemia Therapy by Eliminating Leukemia Stem Cells through Inhibition of Adenosine Deaminase that Acts on RNA
Jian Yu, PhD Role of PUMA-mediated Apoptosis in Cancer Therapy
Theme: Cancer Risk, Prevention, and Survivorship
Talal El-Hefnawy, MD, PhD Lung Cancer Link Risk Assessment and Dietary Intervention for Environmental Estrogens
Donna Posluszny, PhD Coping with Stem Cell Transplantation in Patients and Caregivers
Theme: Cancer Stem Cells
Laure Croisille, MD, PhD Identification and Role of Perivascular Cells in Human Prostate Cancer
Albert Deleo, PhD Immunotherapy of Cancer Stem Cells
Byeong-Chel Lee, PhD Cancer Therapeutics by Targeting Cancer Stem Cells
Theme: Cancer Immunology and Immunotherapy
Lisa Butterfield, PhD Determinant Spreading in Melanoma Immunotherapy
William Chambers, PhD Natural Killer Cell Regulation of Immune Responses: Interactions between CD161 and Clr Markers in Co-Activation of Natural Killer and Dendritic Cells
Soldano Ferrone, MD, PhD Immunity to High Molecular Weight-Melanoma Antigen (HMW-MAA)
Theme: Molecular Mechanisms of Cancer Development and Progression
Ole Gjoerup, PhD Checkpoint and Cancer Mechanisms Investigated using an SV40 T Antigen Model
Richard Steinman, MD, PhD Control of mRNA Stability by Cytokines in Myeloblasts
Birgitte Wittschieben, PhD Determination of Specific Functions and Regulation of DNA Polymerases involved in DNA Damage Tolerance in Normal and Cancer Cells
John Wittschieben, PhD Influence of DNA Polymerase Zeta Subunit Rev3L on Tumor Development in Mice
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Leonard Appleman, MD, PhD Discovery of Novel Drug Targets and Therapeutics in Prostate Cancer
Jan Beumer, PharmD, PhD Epigenetically Targeted Therapy for Ovarian Cancer
Thomas Conrads, PhD Development of a Mass Spectrometry Test for Invasive Breast Cancer
Bino John, PhD "Junk-DNA": a New Paradigm in the Struggle against Cancer
Daniel Johnson, PhD Translational Studies to Improve Therapy for Leukemia
Luyuan Li, PhD Development of RHBDF1 siRNA as a Therapeutic Agent for Cancers of Epithelial Cells
Bo Liu, PhD Auto-Feedback Mechanism of Beta-catenin and Cancer Therapies
Markus Mapara, MD, PhD Molecular Targeting of Inflammatory Signaling Pathways for Achieving Graft-Versus-Leukemia (GVL) Effects without Graft-Versus-Host Disease
Harish Srinivas, PhD Estrogen Receptors as Potential Targets for Lung Cancer Treatment
Wenjun Wang, MD, PhD Foxp3 is a Novel Target for Melanoma Prevention and Therapy
Theme: Cancer Risk, Prevention, and Survivorship
Faina Linkov, PhD, MPH Comparison of Effects of Different Types of Exercise on Immune Parameters and Serum Biomarkers
Theme: Cancer Immunology and Immunotherapy
Anthony Brickner, PhD Exploiting the Human PANE1 Protein for Precisely Targeted Therapy of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphomas
Lisa Butterfield, PhD Determinant Spreading in Melanoma Immunotherapy
Eva Pizzoferrato, PhD Immune Targeting of Survivin Peptide Epitopes in Patients with Hematologic Malignancies
Nikola Vujanovic, MD, PhD Cancer Therapy by Enhancing Natural Killer (NK) Cell-Dendritic Cell (DC) Cross-Talk via Membrane-Bound Molecules
Hassane Zarour, MD Optimization of Cancer Vaccines for Melanoma and other Solid Tumors
Theme: Molecular Mechanisms of Cancer Development and Progression
William Chambers, PhD Evaluating the Effects of Stress on Spontaneous Breast Cancer Development: A New Paradigm
Shi-Yuan Cheng, PhD Signaling Mechanisms in Glioma Invasion
Stefan Duensing, MD Genomic Instability Induced by Tumor Viruses: Identification of Molecular Mechanisms and Possible Therapeutic Implications
Richard Steinman, MD, PhD The Role of Post-Transcriptional Regulation in Differentiation and Cancer
Yong Wan, PhD Functional Proteomic Study of Proteolysis in DNA Damage/Repair and Tumor Formation
Joel Weissfeld, MD, MPH Signaling Mechanisms in Glioma Invasion
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Elieser Gorelik, MD, PhD A New Approach in Anticancer Drug Screening
Pamela Hershberger, PhD Improving Vitamin D as a Treatment for Lung Cancer by Preventing its Destruction within Tumor Cells
Ruth Modzelewski, PhD Tumor Blood Vessel Targeting as a Strategy for Cancer Intervention to Improve Diagnosis and Targeted Treatment Options
Mark Nichols, PhD Understanding Resistance to Antihormone Therapy in Breast Cancer Treatment: Developing New RNA Interference Tools and Drug Screens to Find Novel and Effective Therapies
Theme: Cancer Risk, Prevention, and Survivorship
Seymour Garte, PhD Emanuela Taioli, MD, PhD Interactions Between Genetic Factors and Environmental Exposures in Human Cancer Causation
Jing Hu, MD, PhD Targeting Deregulated Transcription Factors and Co-factors for Cancer Prevention
Donna Posluszny, PhD Brief Psychosocial Intervention for Head and Neck Cancer Patients and Partners
Sanjay Srivastava, PhD Shivendra Singh, PhD Prostate Cancer Prevention by Guggulsterone, a Constituent of Indian Ayurvedic Medicinal Plants
Theme: Cancer Stem Cells
Qingde Wang, MD, PhD Regulation of NF-kB Signaling Pathway in Cancer Stem Cells and its Clinical Implications
Theme: Cancer Immunology and Immunotherapy
Lisa Butterfield, PhD John Kirkwood, MD Determinant Spreading in Melanoma Immunotherapy
Albert Deleo, PhD Aldehyde Dehydrogenase Type 1 (APDH1), a Novel Tumor Antigen for Development of Vaccines for Immunotherapy of Squamous Cell Carcinoma of the Head and Neck
Michael Lotze, MD Improving on Interleukin 2 Therapy for Cancer
Hannah Rabinowich, PhD Harnessing Ncl-1 Anti-Apoptotic Mechanisms for the Protection of T Lymphocytes from Prostate Cancer-Induced Dysfunction
Nikola Vujanovic, MD, PhD Cancer Immunotherapy by Stimulation of NK Cell-Dendritic Cell Cross Talk
Theme: Molecular Mechanisms of Cancer Development and Progression
Saleem Khan, PhD Gene Expression Analysis of HPV-Associated Squamous Cell Carcinoma of the Head and Neck
Theme: Cancer Biomarkers for Early Detection and Development of Targeted Therapies
Charles Brown, MD, PhD Targeted Imaging of Cancer/Peptide-guided Magnetic Resonance Agent
Luyuan Li, PhD Development of Anti-Angiogenesis Experimental Therapeutics
Anna Lokshin, PhD Luminex Analysis of Multiple Serum Markers for Ovarian Cancer
Mark Nichols, PhD RHP - Functional siRNA Genomics
Jian Yu, PhD Role of PUMA in Modulating Therapeutic Responses of Lung Cancer
Theme: Cancer Risk, Prevention, and Survivorship
Uddhav Kelavkar, PhDM Prostate Cancer Pilot Study of Afro-Caribbean/Caucasian Populations
Theme: Cancer Stem Cells
Laure Croisille, MD, PhD Identification of Prostate Cancer "Stem Cells"
Vera Donnenberg, PhD Metastatic Breast Cancer Tumor Stem Cells
Theme: Cancer Immunology and Immunotherapy
Lisa Butterfield, PhD Determinant Spreading in Melanoma Immunotherapy
Gurkamal Chatta, MD Immunobiology of Cancer and Aging: Translational Research
Robert Ferris, MD, PhD, FACS Targeting HPV E7 Protein for Immunotherapy of Head and Neck Patients